title: Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
abstract: Cutaneous T-cell lymphomas (CTCLs) are a group of skin-invasive malignancies of clonally derived T lymphocytes. Mycosis fungoides and Sézary syndrome, characterized by the proliferation of CD4+ T cells, are the most common forms of CTCL. Among these latter disorders, the host antitumor response appears to play an important role in disease control. Thus, systemic therapeutic agents are used in an effort to augment the host antitumor response while selectively targeting the malignant cells. Both new and old biologic response-modifying treatment options currently used to treat CTCL are reviewed.
authors.affiliation: University of Pennsylvania, Philadelphia, USA.
authors.forename: Alain H
authors.initials: AH
authors.lastname: Rook
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Junkins-Hopkins
authors.forename: Karen S
authors.initials: KS
authors.lastname: McGinnis
authors.forename: Maria
authors.initials: M
authors.lastname: Wysocka
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Richardson
authors.forename: Jeanne B
authors.initials: JB
authors.lastname: Budgin
authors.forename: Suzanne
authors.initials: S
authors.lastname: Everitts
authors.forename: Carmela C
authors.initials: CC
authors.lastname: Vittorio
mesh_terms: D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077610:Bexarotene; D016207:Cytokines / Q000627:therapeutic use*; D004167:Diphtheria Toxin / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D018664:Interleukin-12 / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000276:immunology; D017893:Photopheresis; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use
chemical_list: D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D016207:Cytokines; D004167:Diphtheria Toxin; D007370:Interferon Type I; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D013764:Tetrahydronaphthalenes; D018664:Interleukin-12; C078456:denileukin diftitox; D007371:Interferon-gamma; D000077610:Bexarotene